TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04133922

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GLP-1
Description: glucagon-like peptide 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GLP-1
Description: glucagon-like peptide 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: we are using to replace basal insulin and to raise insulin concentrations during the insulin clamp

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: we are using to replace basal insulin and to raise insulin concentrations during the insulin clamp

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dextrose 20 % in Water
Description: We are using Dextrose to maintain Euglycemia during the insulin clamp

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dextrose 20 % in Water
Description: We are using Dextrose to maintain Euglycemia during the insulin clamp
Study: NCT02537795

Intervention type: DEVICE
Intervention: deep brain stimulation
Description: Electrical stimulation of the anterior limb of the internal capsule or bed nucleus of the stria terminalis

Intervention type: PROCEDURE
Intervention: anterior capsulotomy
Study: NCT02330328

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No Telemetry Monitoring

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Telemetry Monitoring
Study: NCT01687556

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: topical EGCG application on acne
Description: two times application of topical EGCG on acne lesion

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: topical EGCG application on acne
Description: two times application of topical EGCG on acne lesion
Study: NCT03657303

Intervention type: DEVICE
Intervention: Magnetic resonance imaging (MRI)
Description: Participants will undergo an initial (baseline) MR examination, followed by repeat MR examinations at approximately 1 month and 1 year following the baseline examination.

Intervention type: DEVICE
Intervention: Magnetic resonance imaging (MRI)
Description: Participants will undergo an initial (baseline) MR examination, followed by repeat MR examinations at approximately 1 month and 1 year following the baseline examination.
Study: NCT02299778

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 13C6-p-aminobenzoic acid
Study: NCT00991952

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alvocidib
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: irinotecan hydrochloride
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT01517880

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sialic Acid Extended Release (SA-ER)
Description: SA-ER will be administered in doses of 3000mg per day or 6000mg per day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will be randomized to the placebo arm for the first 24 weeks of the study. Then, subjects in this arm will be re-randomized into either the 3,000 mg per day or 6,000 mg per day arm for the remaining 24 weeks of the study (total study duration 48 weeks).
Study: NCT01978704

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adjustment of pre-prandial insulin doses on the bases of glycaemic load of the meal

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Adjustment of pre-prandial insulin doses on the bases of carbohydrates content of the meal
Study: NCT02566720

Intervention type: DRUG
Group type: OTHER
Intervention: Amantadine
Description: Participants will initially receive amantadine at the starting dose of 50mg twice daily either by mouth or feeding tube. The dosage will increase every week by 50mg twice daily (100mg total dose increase) up to the target dose of 200mg twice daily. These are the usual doses and rate of increase that are offered to patients with brain injury.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: MRI Tractography Study
Description: Participants will initially receive a baseline MRI Tractography scan. The size of RAS fiber tracts will be measured prior to initiating treatment and near the time of discharge from the rehabilitation hospital or at approximately ninety-days.
Study: NCT03010540

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MORPHINE PLUS FENTANYL
Description: Effect Of Morphine Plus Fentanyl On Emergence Delirium

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Effect Of Fentanyl Only On Emergence Delirium
Study: NCT01871506

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Care (SC)
Description: 1. Initial counseling session: The initial counseling session will last approximately 45 minutes and will be conducted in-person or by phone by a tobacco treatment counselor. The session will be structured in a 5 As format and utilize Motivational Interviewing (MI) techniques.~2. 3 Weekly Follow-up Counseling Sessions: SC Patients will be offered 3 weekly proactive follow-up sessions, concentrated on quitting and staying quit throughout cancer treatment.~3. Medication advice: The tobacco counselor will advise SC subjects to use smoking cessation medication to assist with their quit. Smoking cessation medication will not be provided by the study free of cost for SC subjects.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive Counseling (IC)
Description: The IC model includes all components of the SC as well as extended counseling support and up to 90 days of free FDA approved smoking cessation medication.~1. Extended counseling support: Participants in the IC group will be offered the same initial 4 counseling sessions as the SC group as well as 4 additional proactive biweekly sessions and 3 monthly booster sessions.~2. Smoking cessation medication: IC participants will be offered a 4-week supply of FDA-approved smoking cessation medication (varenicline, bupropion or nicotine replacement therapy) of their choice, with the option to renew the medication twice for up to 90 days of free medication. Participants are not required to take smoking cessation medication.
Study: NCT01568723

Intervention type: GENETIC
Intervention: response to therapy
Description: evaluate specific markers for response to therapy at specific intervals pre and post therapy
Study: NCT04379752

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cold-atmospeheric pressure plasma activated aqueous-alcohol solution treatment
Description: Cold plasma is generated and applied to carrier liquid. Subjects are provided with the liquid to apply to the treated area
Study: NCT03006211

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nitrogen protoxide

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nitrogen protoxide

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen
Study: NCT04475341

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS + Bone Marrow Aspirate Concentrate
Description: Both groups of patients are surgically treated with arthroscopic bone marrow stimulation (BMS). The control group will receive BMS alone but with a sham-treatment consisting of a Jamashidi (bone marrow aspiration) needle puncture of the iliac crest. The aspirated bone marrow concentrate will be collected and sent for cell characterisation but will not be inserted in the talar OCD. The intervention group will also receive arthroscopic BMS. From this group, BMAC from the iliac crest will be taken by the same needle puncture. Part of this concentrate will be sent for cell characterisation. Another part will be implanted into the talar OCD.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: BMS alone
Description: Both groups of patients are surgically treated with arthroscopic bone marrow stimulation (BMS). The control group will receive BMS alone but with a sham-treatment consisting of a Jamashidi (bone marrow aspiration) needle puncture of the iliac crest. The aspirated bone marrow concentrate will be collected and sent for cell characterisation but will not be inserted in the talar OCD. The intervention group will also receive arthroscopic BMS. From this group, BMAC from the iliac crest will be taken by the same needle puncture. Part of this concentrate will be sent for cell characterisation. Another part will be implanted into the talar OCD.
Study: NCT04490629

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lyoplant Onlay
Description: Lyoplant Onlay is a kind of latest artificial Dura Mater

Intervention type: DEVICE
Group type: OTHER
Intervention: DURAFORM
Description: DURAFORM is a kind of conventional artificial Dura Mater
Study: NCT01028352

Intervention type: DRUG
Group type: OTHER
Intervention: Duloxetine
Description: Patients will be treated with open-label duloxetine:~* 30 mg daily x 7 days, then~* 60 mg daily x 3 weeks, then~* If a patient believes she has experienced a sufficient reduction in pain after 4 weeks of therapy, she will continue taking 60 mg daily for weeks 5-8~* If a patient does not believe she has experienced a sufficient reduction in pain after 4 weeks of therapy, she will have the option of increasing the dose to 60 mg twice daily for weeks 5-8.~* After completion of 8 weeks of therapy, patients who wish to discontinue therapy will taper off the drug over 1 week (50% decrease for 4 days, then additional 50% decrease for 3 days). Patients may continue therapy off-study at the discretion of their treating physician.
Study: NCT03355027

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80Mg Tablet
Description: Patients will be instructed to take once daily at night. Atorvastatin will be the preferred statin option for those with eGFR \< 60 ml/min/1.73m2. Patient may be required to complete a 4 week run-in period on a statin prior to entering the study (dependent on eligibility)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin 80Mg Tablet
Description: Patients will be instructed to take once daily at night. Atorvastatin will be the preferred statin option for those with eGFR \< 60 ml/min/1.73m2. Patient may be required to complete a 4 week run-in period on a statin prior to entering the study (dependent on eligibility)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20Mg Tablet
Description: Patients will be instructed to take once daily at night. Rosuvastatin only to be prescribed if atorvastatin and simvastatin are not previously tolerated. Patient may be required to complete a 4 week run-in period on a statin prior to entering the study (dependent on eligibility)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin 20Mg Tablet
Description: Patients will be instructed to take once daily at night. Rosuvastatin only to be prescribed if atorvastatin and simvastatin are not previously tolerated. Patient may be required to complete a 4 week run-in period on a statin prior to entering the study (dependent on eligibility)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 40Mg Tablet
Description: Patients will be instructed to take once daily at night. Rosuvastatin only to be prescribed if atorvastatin and simvastatin are not previously tolerated. Patient may be required to complete a 4 week run-in period on a statin prior to entering the study (dependent on eligibility)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin 40Mg Tablet
Description: Patients will be instructed to take once daily at night. Rosuvastatin only to be prescribed if atorvastatin and simvastatin are not previously tolerated. Patient may be required to complete a 4 week run-in period on a statin prior to entering the study (dependent on eligibility)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin 80mg
Description: Patients will be instructed to take once daily at night. Patient may be required to complete a 4 week run-in period on a statin prior to entering the study (dependent on eligibility)
Study: NCT02193061

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rotarix

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rotarix

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rotarix

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rotarix

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rotarix

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rotarix

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: RotaTeq

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: RotaTeq

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: RotaTeq

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: RotaTeq

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: RotaTeq

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: RotaTeq
Study: NCT00909610

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ursodiol
Description: Ursodiol Tablets, 500 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Urso Forte™
Description: Urso Forte™ Tablets, 500 mg
Study: NCT02597660

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Somatropin
Description: Active drug
Study: NCT02813460

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation H1 (ALS-008176)
Description: 60 mg/mL ALS-008176 oral suspension with concentration 1 of sucralose (maximum 12 mg/mL) and best flavor 2 from session 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation H2 (ALS-008176)
Description: 60 mg/mL ALS-008176 oral suspension with concentration 2 of sucralose (maximum 12 mg/mL) and best flavor 2 from session 1.
Study: NCT04640727

Intervention type: PROCEDURE
Intervention: open reduction
Description: A sterile tourniquet is applied and an oblique posterolateral skin incision is made. Superficial dissection is carried out in the plane of the fracture hematoma until the distal lateral corner of the proximal fragment is identified. Once the metaphyseal side of the fracture has been identified, the dissection is carried across the joint to expose the medial articular surface. After exposure of the proximal fragment, the orientation of the distal fragment is defined and the soft tissues are sharply released off the anterior aspect of the distal fragment, with extension carried distally to the radial head. After irrigation and débridement of the fracture hematoma, the distal fragment is reduced with a towel clip. It is important to judge the reduction at the level of the articular surface rather than the metaphysis because plastic deformation or comminution of the metaphyseal fragment may be present. Pins (usually 0.062 inch) are placed percutaneously to secure the fracture.

Intervention type: PROCEDURE
Intervention: closed reduction
Description: we applied a gentle varus force to the elbow while the patient was under general anesthesia, and we attempted to reposition the rotated fragment by directly pushing or by using Kirschner wires as joysticks . After repositioning, we applied gradual direct compression to the distal fracture fragment anteromedially.We then applied slight valgus force to the elbow with the forearm supinated and the elbow fully extended to maintain the reduction. After the fracture reduction was confifirmed to be within 2 mm, especially as seen on the anteroposterior, lateral radiographs,and internal obliquewe used smooth Kirschner wires to perform percutaneous pinning
Study: NCT02597660

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bacteriostatic saline
Description: Placebo, the diluent used to reconstitute somatropin

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Progressive exercise program
Description: Over a 12 week period beginning at the second study visit patients will perform a standard of care eccentric exercise training regime. Each session consists of three bilateral exercises: leg press, back squat, and hack squat. Subjects will complete four sets in each exercise with a 2-3 minute rest between sets. The repetitions/loads are: 15 repetition maximum (RM) week 1, 12RM weeks 2-3, 10RM weeks 4-5, 8RM weeks 6-8 and 6RM weeks 9-12. All exercises are performed from complete 0º to 90º of knee flexion and back again. Each of the eccentric and concentric phases will occur over a period of 3 seconds, respectively for a total of 6 seconds per contraction.
Study: NCT02367846

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combined Oral Contraceptive (COC)
Description: The proposed study is a preclinical, multi-site trial comparing the short-term effects of oral vs. non-oral ethinyl estradiol on net bone calcium balance. A prospective crossover study with repeated measures and a simple random assignment will be used to test the effects of 49 days of COC use on bone metabolism using 41Ca to determine net bone calcium balance. Subjects will be randomized to receive COC during either the first or second intervention period.
Study: NCT03355027

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin 80mg
Description: Patients will be instructed to take once daily at night. Patient may be required to complete a 4 week run-in period on a statin prior to entering the study (dependent on eligibility)
Study: NCT04648176

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Moses technology
Description: Using Holmium laser with Moses technology or conventional one
Study: NCT02597660

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Progressive exercise program
Description: Over a 12 week period beginning at the second study visit patients will perform a standard of care eccentric exercise training regime. Each session consists of three bilateral exercises: leg press, back squat, and hack squat. Subjects will complete four sets in each exercise with a 2-3 minute rest between sets. The repetitions/loads are: 15 repetition maximum (RM) week 1, 12RM weeks 2-3, 10RM weeks 4-5, 8RM weeks 6-8 and 6RM weeks 9-12. All exercises are performed from complete 0º to 90º of knee flexion and back again. Each of the eccentric and concentric phases will occur over a period of 3 seconds, respectively for a total of 6 seconds per contraction.
Study: NCT02813460

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation H2 (ALS-008176)
Description: 60 mg/mL ALS-008176 oral suspension with concentration 2 of sucralose (maximum 12 mg/mL) and best flavor 2 from session 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation H2 (ALS-008176)
Description: 60 mg/mL ALS-008176 oral suspension with concentration 2 of sucralose (maximum 12 mg/mL) and best flavor 2 from session 1.
Study: NCT02597660

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Patellar tendon biopsy
Description: Bilateral biopsies will be performed on an elective basis, although the investigators will aim to have 8 subjects in each group receive the biopsy. Biopsies will be obtained at the 26 week time point. The data obtained from the biopsy will help address the mechanism behind observed changes in outcome scores, physical measurements or imaging studies. The biopsy will be performed under ultrasound guidance and using sterile technique with a disposable 14G, 2cm biopsy instrument.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Patellar tendon biopsy
Description: Bilateral biopsies will be performed on an elective basis, although the investigators will aim to have 8 subjects in each group receive the biopsy. Biopsies will be obtained at the 26 week time point. The data obtained from the biopsy will help address the mechanism behind observed changes in outcome scores, physical measurements or imaging studies. The biopsy will be performed under ultrasound guidance and using sterile technique with a disposable 14G, 2cm biopsy instrument.
Study: NCT02209571

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Venous blood markers
Description: Routine venous blood sampling

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Venous blood markers
Description: Routine venous blood sampling
Study: NCT00076817

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALVAC-HIV (vCP205)
Description: Canarypox virus vector vaccine

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: ALVAC-HIV (vCP205)
Description: Canarypox virus vector vaccine placbo
Study: NCT04648176

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Moses technology
Description: Using Holmium laser with Moses technology or conventional one
Study: NCT02813460

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation H2 (ALS-008176)
Description: 60 mg/mL ALS-008176 oral suspension with concentration 2 of sucralose (maximum 12 mg/mL) and best flavor 2 from session 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation H2 (ALS-008176)
Description: 60 mg/mL ALS-008176 oral suspension with concentration 2 of sucralose (maximum 12 mg/mL) and best flavor 2 from session 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation H2 (ALS-008176)
Description: 60 mg/mL ALS-008176 oral suspension with concentration 2 of sucralose (maximum 12 mg/mL) and best flavor 2 from session 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation H3 (ALS-008176)
Description: 60 mg/mL ALS-008176 oral suspension with concentration 3 of sucralose (maximum 12 mg/mL) and best flavor 2 from session 1.
Study: NCT02367846

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Contraceptive Vaginal Ring (CVR)
Description: The proposed study is a preclinical, multi-site trial comparing the short-term effects of oral vs. non-oral ethinyl estradiol on net bone calcium balance. A prospective crossover study with repeated measures and a simple random assignment will be used to test the effects of 49 days of CVR use on bone metabolism using 41Ca to determine net bone calcium balance. Subjects will be randomized to receive CVR during either the first or second intervention period.
Study: NCT01083108

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Roux-en-Y Gastric Bypass
Description: The surgical group will be studied before and 6 days after bariatric surgery.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Caloric Restriction
Description: The non-surgical group will be studied before and after receiving a hypocaloric diet for 6 days mimicking the typical postoperative diet.
Study: NCT02426814

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inhaler sensor
Description: Inhaler sensor strap that tracks inhaler use.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Inhaler sensor
Description: Inhaler sensor strap that tracks inhaler use.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile application for asthma adherence
Description: Mobile phone application that sends reminders and allows patients to self-manage their medication adherence.
Study: NCT00991952

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies